KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Operating Income (2019 - 2025)

Historic Operating Income for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Q3 2025 value amounting to $29.7 million.

  • Aurinia Pharmaceuticals' Operating Income rose 15319.2% to $29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.0 million, marking a year-over-year increase of 31413.8%. This contributed to the annual value of -$4.7 million for FY2024, which is 9488.83% up from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Operating Income stood at $29.7 million for Q3 2025, which was up 15319.2% from $20.1 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' 5-year Operating Income high stood at $29.7 million for Q3 2025, and its period low was -$50.5 million during Q1 2021.
  • Its 5-year average for Operating Income is -$16.7 million, with a median of -$16.3 million in 2023.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Operating Income crashed by 8678.12% in 2021, and later soared by 142736.29% in 2025.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Operating Income stood at -$32.7 million in 2021, then increased by 14.08% to -$28.1 million in 2022, then fell by 5.6% to -$29.7 million in 2023, then skyrocketed by 94.38% to -$1.7 million in 2024, then soared by 1882.2% to $29.7 million in 2025.
  • Its Operating Income stands at $29.7 million for Q3 2025, versus $20.1 million for Q2 2025 and $21.8 million for Q1 2025.